GSK-49653/183



A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Avandia™ XR and AVANDIA™ (4mg BD) in Patients with Type 2 Diabetes
rosiglitazone
49653/183
Diabetes Mellitus, Type 2
Phase 3
 
A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
February 2015